Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial

Japanese open label RCT (n=1,734) found that pitavastatin plus ezetimibe did not reduce a composite endpoint of all-cause death, non-fatal myocardial infarction or stroke, unstable angina and revascularisation vs pitavastatin alone